Octapharma, Toronto, ON

The story of Octapharma began in the 1980s, when we pioneered the introduction of virally inactivated Factor VIII for the treatment of hemophilia patients. Since then, we have introduced several life saving or life enhancing treatments that have helped people lead normal lives. We have provided innovative solutions that include helping several countries meet their self-sufficiency goals for plasma products by fractionating their collected plasma. Fractionation involves the extraction of highly specific proteins or factors that play a crucial part in the coagulation cascade to develop a series of therapeutically beneficial treatments. Each of these products is treated with solvent-detergent technology and other additional viral inactivation methods to ensure unmatched viral inactivation and product purity. The end result of this is an unsurpassed array of highly beneficial biopharmaceutical products.